About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristant #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Subscribe to this blog's feed

Contact the Docs

Docs on Twitter


Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Bristol-Myers Squibb and Pfizer Enter into Anticoagulant and Metabolic Disorder Collaborations | Main | It's Time to Stop the Hypocrisy over Stem Cell Patents - Part II »

April 26, 2007

SciClone Acquires Rights to Potential Pancreatic Cancer Compound from Avantogen

    By Christopher P. Singer --

Sciclone_logo In an April 26, 2007 press release SciClone Pharmaceuticals Inc. announced that it acquired exclusive rights in the U.S. and Canada to develop and commercialize a compound in the clinical stage for treatment of pancreatic cancer.  The drug, RP101, was brought to Phase I clinical trials as a combination treatment with gemcitabine by Resistys, Inc., a wholly-owned subsidiary of Avantogen Oncology, Inc.  In acquiring the rights to RP101 from Avantogen, SciClone expects to initiate a Phase II clinical study to assess the compound's effectiveness in treating late-stage pancreatic cancer by the end of 2007.

Avantogen_logo Under the terms of the agreement, SciClone receives exclusive development and commercialization rights in the U.S. and Canada, in exchange for payments to Resistys, including an upfront payment of about $1.7 million, a $1.3 million milestone payment upon initiation of the Phase II clinical study, post Phase III regulatory and commercial payments of up to $22 million, and royalty payments on future sales.

Posted at 11:31 PM in Licensing |

Comments

Dear friends!
My father have Pancreatic Cancer(caput).
Have a chance?

Posted by: Grigoriy Bogorad | September 21, 2007 at 04:10 AM

The comments to this entry are closed.

March 2019

Sun Mon Tue Wed Thu Fri Sat
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31            

Categories

Archives

More...